米力农联合重组人脑利钠肽治疗冠心病室性期前收缩的疗效

发布时间：2018-04-29 14:13

本文选题：米力农 + 重组人脑利钠肽　；参考：《中国老年学杂志》2017年23期

【摘要】：目的探讨米力农联合重组人脑利钠肽对冠心病室性期前收缩患者治疗效率、心功能及不良心血管事件发生的影响。方法选取冠心病室性期前收缩患者80例,依据随机数字表法分为米力农组和米力农联合重组人脑利钠肽治疗组(联合治疗组)各40例,比较两组治疗效率、心功能及不良心血管事件发生率。结果联合治疗组血清N末端-脑利钠肽前体(NT-proBNP)水平显著低于米力农组,收缩末内径、舒张末内径显著小于米力农组,治疗效率显著高于米力农组,不良心血管事件发生率显著低于米力农组(均P0.05)。结论米力农联合重组人脑利钠肽能够有效提高冠心病室性期前收缩患者的治疗效率,改善患者的心功能,降低患者的不良心血管事件发生率。
[Abstract]:Objective to investigate the effects of milrinone combined with recombinant human brain natriuretic peptide on the treatment efficiency, cardiac function and adverse cardiovascular events in patients with coronary heart disease (CHD). Methods 80 patients with coronary heart disease were randomly divided into two groups: milrinone group and milrinone combined with recombinant human brain natriuretic peptide group (combined treatment group). Cardiac function and incidence of adverse cardiovascular events. Results the level of NT-proBNPs in the combined treatment group was significantly lower than that in the milrinone group, and the end systolic and diastolic diameter were significantly lower than those in the milrinone group, and the therapeutic efficiency was significantly higher than that in the milrinone group. The incidence of adverse cardiovascular events was significantly lower in milrinone group than that in milrinone group (all P 0.05). Conclusion milrinone combined with recombinant human brain natriuretic peptide can effectively improve the treatment efficiency of patients with coronary heart disease, improve the heart function and reduce the incidence of adverse cardiovascular events.
【作者单位】：辽宁中医药大学附属医院;
【分类号】：R541.4

【相似文献】